ESTRO 2024 - Abstract Book

S1708

Clinical - Lung

ESTRO 2024

Conclusion:

Although it remains a challenging, high-risk clinical scenario, SABR for central and ultra-central tumors represents an effective and safe treatment option for patients with early-stage non-small cell lung cancer and lung metastasis. Despite the lower administered dose, all radiological lobar stenosis occurred for lesions located within 1 cm from the trachea or main bronchi, confirming the criticality of these structures for dose prescribing and planning.

Keywords: SABR; central lung tumors; bronchial toxicity

References:

1. Chang JY, Bezjak A, Mornex F; IASLC Advanced Radiation Technology Committee. Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned. J Thorac Oncol. 2015

2. Tekatli H, Giraud N, van Eekelen R, Lagerwaard FJ, Senan S. Ten years outcomes after SABR in central and ultracentral primary lung tumors. Radiother Oncol. 2023

2027

Digital Poster

Postoperative radiotherapy for thymoma: a single center 20 years experience.

Marta López Valcárcel, Irma Zapata Paz, Jesús Romero Fernández, Joaquin Velasco Jiménez, Sofia Córdoba Largo, Beatriz Gil Haro, Maria Hernández Miguel, Raquel Benlloch Rodriguez, Sofia Santana Jimenez, Francisco Javier Martinez Paredes, Sara Pérez Mata, MªIsabel García Berrocal, Cristina De la Fuente Alonso

Puerta de Hierro University Hospital, Radiation Oncology, Majadahonda, Spain